Physician profile
Uma Purighalla
NPI 1467416016
$896.36
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $67.97 · 2021: $181.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $186.09 | 2019-2021 | |
| Pfizer INC. | $153.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $98.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $90.40 | 2019-2020 | |
| Allergan, INC. | $72.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.74 | 2019 | |
| Glaxosmithkline, LLC. | $57.19 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $42.79 | 2019 | |
| Abbvie INC. | $40.59 | 2021 | |
| Lilly USA, LLC | $25.99 | 2019 | |
| Genentech USA, INC. | $15.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.47 | 2019 | |
| Astellas Pharma US INC | $14.95 | 2019 | |
| Novo Nordisk INC | $12.73 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Purighalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.